Chronic antidepressant treatment and mouse brain 3H-imipramine binding.
Chronic pretreatment of mice with the monoamine oxidase type B inhibitor (-)deprenyl resulted in an increase in the density of cerebral cortical 3H-imipramine binding sites and a decrease in the density of cerebral cortical beta-adrenergic receptors. In contrast, pretreatment of mice with the tricyclic antidepressants imipramine and desipramine did not alter the density of cerebral cortical 3H-imipramine binding sites. Imipramine and desipramine treatment decreased the density of beta-adrenergic receptors. Haloperidol pretreatment resulted in an increase in the density of striatal D-2 dopamine receptors, but did not alter the density of cerebral cortical 3H-imipramine binding sites or beta-adrenergic receptors. These data suggest that brain 3H-imipramine binding sites can be regulated by pharmacological pretreatment, but that this regulation may not occur for all antidepressants.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects*; D003891:Desipramine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D007099:Imipramine / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects; D017448:Receptors, Dopamine D2; D012642:Selegiline / Q000494:pharmacology
D000928:Antidepressive Agents; D011943:Receptors, Adrenergic, beta; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D012642:Selegiline; D006220:Haloperidol; D007099:Imipramine; D003891:Desipramine